Clinical Trial Update: Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ensatinib for patients with ALK-positive non-small cell lung cancer who have developed resistance to a second-generation ALK-T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ensatinib (ensatinib)

Snippet

Sponsor: Li Zhang, MD | Conditions: The Diagnosis Was ALK Positive NSCLC, Second Generation ALK-TKI is Resistant | Phase 2 | Status: UNKNOWN